From the 493 advanced NSCLC patients who received ICI during the study period at the three institutions, 385 were excluded based on the following criteria: no adenocarcinoma (n = 209), received cytotoxic chemotherapy concurrent with ICI (n = 76), status of TTF‐1 and/or PD‐L1 missing (n = 100). The gene discussed is CD274; the disease is adenocarcinoma.